What are the recommended dosing adjustments for anti‑tuberculosis therapy (isoniazid, rifampin, pyrazinamide, ethambutol) in patients with renal impairment, including those on chronic hemodialysis?

Anti-Tuberculosis Drug Dosing in Renal Impairment

For patients with creatinine clearance <30 mL/min or on hemodialysis: Isoniazid and rifampin require NO dose adjustment (300 mg daily or 900 mg/600 mg three times weekly), while pyrazinamide and ethambutol MUST be changed to three-times-weekly dosing (25-35 mg/kg and 20-25 mg/kg respectively) and should NEVER be given daily. 1

Core Dosing Principles

The fundamental approach differs from typical renal dosing: increase the dosing interval rather than decrease the dose to maintain peak drug concentrations needed for bactericidal activity while avoiding accumulation 1. This strategy is critical because reducing doses lowers peak serum concentrations and compromises treatment efficacy.

Drugs Requiring NO Adjustment

Isoniazid and Rifampin:

• Both are hepatically metabolized and can be dosed conventionally in renal insufficiency 1
• Isoniazid: 300 mg once daily OR 900 mg three times weekly
• Rifampin: 600 mg once daily OR 600 mg three times weekly
• Rifampin is NOT cleared by hemodialysis due to high molecular weight, extensive tissue distribution, high protein binding, and rapid hepatic metabolism 2
• Isoniazid is minimally removed by hemodialysis 3

Drugs Requiring Frequency Adjustment

Pyrazinamide:

• Although hepatically metabolized, its metabolites (pyrazinoic acid and 5-hydroxy-pyrazinoic acid) accumulate in renal insufficiency 1
• Dose: 25-35 mg/kg three times weekly (NOT daily)
• Pyrazinamide is significantly dialyzed (45% median recovery in dialysate) 3
• Must be given AFTER hemodialysis to avoid drug loss 1

Ethambutol:

• Approximately 80% renally cleared and accumulates in renal insufficiency 1
• Dose: 20-25 mg/kg three times weekly (NOT daily) (Note: 2016 guidelines increased from 15-25 mg/kg in 2003 guidelines) 1
• Minimally removed by hemodialysis (2% median recovery) 3
• Critical caveat: Monitor serum drug concentrations to minimize dose-related ocular toxicity 2

Hemodialysis-Specific Considerations

Timing is crucial: Administer ALL anti-tuberculosis drugs immediately after hemodialysis on dialysis days 1. This approach:

• Facilitates directly observed therapy (three times weekly)
• Avoids premature drug removal during dialysis
• Eliminates need for supplemental dosing

Dialysis clearance data 3:

• Pyrazinamide: 45% removed (median hemodialysis clearance 270 mL/min) - clinically significant
• Isoniazid: 9% removed (124 mL/min clearance) - not clinically significant
• Rifampin: 4% removed (40 mL/min clearance) - not clinically significant
• Ethambutol: 2% removed (46 mL/min clearance) - not clinically significant

Borderline Renal Function (CrCl 30-50 mL/min)

Insufficient data exist for definitive recommendations in this range 1. The expert consensus approach:

• Use standard doses initially
• Measure serum drug concentrations at 2 and 6 hours post-dose to optimize dosing 1
• Consider 24-hour urine collection to accurately define degree of renal insufficiency before making regimen changes 1

Essential Monitoring

Therapeutic drug monitoring should be strongly considered in all patients with renal insufficiency, particularly for 2:

• Ethambutol (to avoid ocular toxicity)
• Pyrazinamide
• Any injectable agents (streptomycin, kanamycin, amikacin, capreomycin)

Additional clinical considerations 2:

• End-stage renal disease patients often have comorbidities (diabetes with gastroparesis) affecting drug absorption
• Multiple concurrent medications may interact with anti-tuberculosis drugs
• Careful clinical and pharmacologic assessment is necessary

Important Caveats

1. Peritoneal dialysis: No data currently available. Begin with hemodialysis dosing recommendations and verify adequacy using serum concentration monitoring 2, 1

2. Clinical outcomes: Real-world data shows that guideline-based renal dosing adjustments achieve similar therapeutic outcomes to non-CKD patients, but adverse events warrant attention, particularly in severe CKD 4

3. Worse baseline outcomes: TB patients with chronic renal failure have worse clinical outcomes than those without renal failure, necessitating close monitoring throughout treatment 1

4. Immunocompromised status: Patients with renal insufficiency or ESRD are immunocompromised, which may affect treatment response 1